About Instil Bio, Inc.
https://instilbio.comInstil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).
CEO
Bronson Crouch
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-08 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
MARSHALL WACE NORTH AMERICA L.P.
Shares:1.45M
Value:$10.4M
BML CAPITAL MANAGEMENT, LLC
Shares:645.6K
Value:$4.64M
CPMG INC
Shares:410.92K
Value:$2.95M
Summary
Showing Top 3 of 42
About Instil Bio, Inc.
https://instilbio.comInstil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $15.01M ▼ | $-13.59M ▲ | 0% | $-2.01 ▲ | $-11.75M ▲ |
| Q2-2025 | $0 | $23.44M ▼ | $-21.39M ▲ | 0% | $-3.24 ▲ | $-19.8M ▲ |
| Q1-2025 | $0 | $30.56M ▲ | $-28.2M ▼ | 0% | $-4.32 ▼ | $-26.82M ▼ |
| Q4-2024 | $0 | $10.73M ▼ | $-11.89M ▲ | 0% | $-1.82 ▲ | $-8.56M ▲ |
| Q3-2024 | $0 | $23.63M | $-23.02M | 0% | $-3.54 | $-20.11M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $79.67M ▼ | $211.77M ▼ | $91.35M ▼ | $120.42M ▼ |
| Q2-2025 | $91.82M ▼ | $230.99M ▼ | $99.32M ▲ | $131.67M ▼ |
| Q1-2025 | $103.65M ▼ | $237.45M ▼ | $92.54M ▼ | $144.91M ▼ |
| Q4-2024 | $113.31M ▼ | $263.57M ▼ | $94.13M ▼ | $169.44M ▼ |
| Q3-2024 | $120.35M | $272.56M | $96.23M | $176.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-13.59M ▲ | $-10.56M ▲ | $8.45M ▲ | $378K ▼ | $-1.76M ▲ | $-10.56M ▲ |
| Q2-2025 | $-21.39M ▲ | $-14.79M ▼ | $-400K ▼ | $6.68M ▲ | $-8.49M ▼ | $-14.79M ▼ |
| Q1-2025 | $-28.2M ▼ | $-4.2M ▲ | $9.61M ▼ | $232K ▼ | $5.69M ▲ | $-4.2M ▲ |
| Q4-2024 | $-11.89M ▲ | $-10.56M ▲ | $13M ▼ | $1.6M ▲ | $3.97M ▲ | $-10.56M ▲ |
| Q3-2024 | $-23.02M | $-20.13M | $19.81M | $159K | $-118K | $-20.13M |
CEO
Bronson Crouch
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-08 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
MARSHALL WACE NORTH AMERICA L.P.
Shares:1.45M
Value:$10.4M
BML CAPITAL MANAGEMENT, LLC
Shares:645.6K
Value:$4.64M
CPMG INC
Shares:410.92K
Value:$2.95M
Summary
Showing Top 3 of 42